Clinical application of PET imaging in the lungs for drug development

Delphine L. Chen

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Currently available methods for assessing lung and airway inflammation are invasive, insensitive, or non-specificfor the inflammatory process and cannot quantify the total pulmonary inflammatory response accurately. Bronchoalveolar lavage remains the gold standard for detection of lung inflammation; however, its limitations include sampling errors and theinvasiveness of the procedure.Positron emission tomography is a non-invasive, highly sensitive imaging technique that can be used to quantify lung-specific inflammation and carries great potential as a biomarker that can be used to assess theefficacy of anti-inflammatory therapies on pulmonary inflammation. This chapter summarizes the clinical evidence supporting the use of PET imaging with [18F]fluorodeoxyglucose(FDG-PET) as a quantitative biomarker for neutrophilic pulmonary inflammation and some of the specific challenges for lung imaging with PET.

Original languageEnglish
Title of host publicationTrends on the Role of PET in Drug Development
PublisherWorld Scientific Publishing Co.
Number of pages22
ISBN (Electronic)9789814317740
ISBN (Print)981431773X, 9789814317733
StatePublished - Jan 1 2012


Dive into the research topics of 'Clinical application of PET imaging in the lungs for drug development'. Together they form a unique fingerprint.

Cite this